Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00365183 · ClinicalTrials.gov registry record · Phase 2
Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Pharmacyclics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
NCT00365183 is a Phase 2 study that was terminated before completion, run by Pharmacyclics. The registered enrollment target is 74 participants.
The verdict
NCT00365183, a Phase 2 study, was terminated before completion, sponsored by Pharmacyclics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
Study Summary
The goals of this study are: * to determine if the combination of two drugs, motexafin gadolinium and pemetrexed, may be an effective treatment for patients with non-small cell lung cancer (NSCLC) who have had one previous chemotherapy regimen that included a platinum containing drug such as cisplatin or carboplatin. * to assess response to treatment in patients with NSCLC six months after beginning study treatment.
Interventions
- DRUG Motexafin gadolinium and pemetrexed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2006-06 |
| Est. Completion | 2008-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00365183
The ClinicalTrials.gov registry entry for NCT00365183 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Motexafin gadolinium and pemetrexed is the first listed.
NCT00365183 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00365183 about?
NCT00365183 is a clinical study titled "Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer". The goals of this study are: * to determine if the combination of two drugs, motexafin gadolinium and pemetrexed, may be an effective treatment for patients with non-small cell lung cancer (NSCLC) who have had one previous chemotherapy regimen that included a platinum containing drug such as cispla...
What is the current status of trial NCT00365183?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2006-06. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00365183?
The interventions under investigation include: Motexafin gadolinium and pemetrexed (DRUG).
Who is sponsoring clinical trial NCT00365183?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.